ReviewFrontiers in immunology2018
Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.PloS one · 2019Trial
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery.Molecular therapy. Oncology · 2026Article
- Review
- NK92 cells stably transfected with CD16 are efficient against multiple myeloma cellsOncoimmunology · 2025Article
- Plasma proteins and herpes simplex virus infection: a proteome-wide Mendelian randomization study.Virus genes · 2025Article
- The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity.Brain : a journal of neurology · 2024Review
- Downregulation of endogenous nectin1 in human keratinocytes by herpes simplex virus 1 glycoprotein D excludes superinfection but does not affect NK cell function.The Journal of general virology · 2024Article
- Molecular Virology of Orthopoxviruses with Special Reference to Monkeypox Virus.Advances in experimental medicine and biology · 2024Review
- Viral- and tumor-reactive natural killer cells.Seminars in immunology · 2023Review
- NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.International journal of molecular sciences · 2021Review
- A HSV1 mutant leads to an attenuated phenotype and induces immunity with a protective effect.PLoS pathogens · 2020Article
- Coronavirus disease 2019 (COVID-19): current status and future perspectives.International journal of antimicrobial agents · 2020Article
- What are the drugs having potential against COVID-19?Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2020Review
- Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.Current pharmacology reports · 2020Review
- Herpes Simplex Virus 1 MicroRNA miR-H28 Exported to Uninfected Cells in Exosomes Restricts Cell-to-Cell Virus Spread by Inducing Gamma Interferon mRNA.Journal of virology · 2019Article
- Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.Frontiers in immunology · 2019Review
- Human NK Cells and Herpesviruses: Mechanisms of Recognition, Response and Adaptation.Frontiers in microbiology · 2019Review
- Porcine NK Cells Stimulate Proliferation of Pseudorabies Virus-Experienced CD8Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Primary infection with Herpes simplex virus type 1 (HSV1) is subclinical or only mildly symptomatic in normal individuals, yet the reason for the body's effective immune defense against this pathogen in the absence of antigen-specific immunity has not been well understood. It is clear that human natural killer (NK) cells recognize and kill HSV1-infected cells, and those individuals who either lack or have functionally impaired NK cells can suffer severe, recurrent, and sometimes fatal HSV1 infection. In this article, we review what is known about the recognition of HSV1 by NK cells, and describe a novel mechanism of innate immune surveillance against certain viral pathogens by NK cells called Fc-bridged cell-mediated cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.